List view / Grid view
30 October 2012 | By kdm communications limited
Tecan and TAP Biosystems, a leading supplier of innovative cell culture systems, have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform. Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D…
30 October 2012 | By GlaxoSmithKline
GlaxoSmithKline announced the start of a Phase III programme...
30 October 2012 | By Abbott
Ensure Complete combines muscle, heart, immune system and bone benefits in one simple shake...
29 October 2012 | By kdm communications limited
Unilabs AB in Eskilstuna, Sweden, is taking advantage of LGC Standards’ LoGiCal reference materials...
29 October 2012 | By GlaxoSmithKline
ViiV Healthcare Ltd and Shionogi & Co., Ltd., have entered into an agreement...
26 October 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company today announced that the European Commission has approved an expanded therapeutic indication for the DPP-4 inhibitor Trajenta® (linagliptin) to include use in combination with insulin in adults with Type 2 Diabetes.
26 October 2012 | By F T I Consulting
Melbourne researchers have developed cows’ milk that can protect human cells from human immunodeficiency virus (HIV)...
26 October 2012 | By Boehringer Ingelheim
Successful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung...
25 October 2012 | By Daiichi Sankyo
Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor...
25 October 2012 | By Novartis
Confidence in the safety and efficacy of seasonal influenza vaccines...
25 October 2012 | By Novo Nordisk
“This meeting will focus on the cardiovascular safety of two products..."
24 October 2012 | By Energy PR
The British Laboratory Managers Association is being launched by GAMBICA...
24 October 2012 | By Abbott
ALK test now available in Europe...
24 October 2012 | By Pfizer
Conditional marketing authorization for XALKORI® in the EU granted...
24 October 2012 | By Abbott
"These data suggest that adalimumab-treated patients were able to reduce steroid usage..."
